


=> d l1; d his; log y
 L1 HAS NO ANSWERS
 L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 17:07:03 ON 11 JAN 2005)

FILE 'REGISTRY' ENTERED AT 17:07:12 ON 11 JAN 2005

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:07:41 ON 11 JAN 2005

L4 2 S L3

FILE 'BEILSTEIN' ENTERED AT 17:08:25 ON 11 JAN 2005

L5 0 S L1 FUL

FILE 'MARPAT' ENTERED AT 17:08:45 ON 11 JAN 2005

L6 3 S L1 FUL

L7 1 S L6 NOT L4

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

118.58

290.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.68



-2.14

STN INTERNATIONAL LOGOFF AT 17:10:07 ON 11 JAN 2005

electronic

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:487529 CAPLUS Full-text
DN 137:63174
TI Preparation of benzo[f]isoindoles as EP4 receptor ligands
IN Giblin, Gerard Martin Paul; Frye, Stephen Vernon; Roomans, Susan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050033	A1	20020627	WO 2001-GB5706	20011220
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	AU 2002017287	A5	20020701	AU 2002-17287	20011220
	EP 1343759	A1	20030917	EP 2001-271356	20011220
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	JP 2004517847	T2	20040617	JP 2002-551530	20011220
	US 2004087624	A1	20040506	US 2003-450639	20031210
PRAI	GB 2000-31295	A	20001221		
	WO 2001-GB5706	W	20011220		
OS	MARPAT 137:63174				
GI					




AB The title compds. [I; R1 = H, halo, alkyl, etc.; R2 = alkyl; R3 = H, O; R4 = H, alkyl; R5 = alkyl (un)substituted Ph, naphthyl, etc.; R7-R10 = H, alkyl, alkoxy, etc.; R11 = H, OH, halo, etc.] which bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunol., bone, neurodegenerative or renal disorder, were prepared E.g., a multi-step synthesis of II which showed pKb of 7.0 or greater in EP4 antagonist assay, was given.

IT 439289-06-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzo[f]isoindoles as EP4 receptor ligands)

RN 439289-06-2 CAPLUS

CN Benzeneacetamide, 4-(4,9-diethoxy-1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:581888 CAPLUS Full-text
 DN 135:147431
 TI Platelet ADP receptor inhibitors. and therapeutic use thereof
 IN Scarborough, Robert M.; Jantzen, Hans-Michael; Huang, Wolin; Sedlock,
 David M.; Marlowe, Charles K.
 PA Cor Therapeutics, Inc., USA
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001057037	A1	20010809	WO 2001-US3585	20010205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2400479	AA	20010809	CA 2001-2400479	20010205
	EP 1257550	A1	20021120	EP 2001-908817	20010205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003522177	T2	20030722	JP 2001-557869	20010205
	US 2002077486	A1	20020620	US 2001-920325	20010802
	US 2004147576	A1	20040729	US 2004-759396	20040115
PRAI	US 2000-180208P	P	20000204		
	US 2000-202072P	P	20000505		
	US 2000-230447P	P	20000906		
	US 2001-775812	A2	20010205		
	WO 2001-US3585	W	20010205		
	US 2003-350883	A1	20030123		

OS MARPAT 135:147431


AB The invention provides compds. including sulfonylurea derivs.,
 sulfonylthiourea derivs., sulfonylguanidine derivs.,
 sulfonylcyanoguanidine derivs., thioacylsulfonamide derivs., and
 acylsulfonamide derivs. which are effective platelet ADP receptor
 inhibitors. These derivs. may be used in various pharmaceutical
 compns., and are particularly effective for the prevention and/or
 treatment of cardiovascular diseases, particularly those diseases
 related to thrombosis. The invention provides a method for preventing
 or treating thrombosis in a mammal comprising the step of administering
 a therapeutically effective amount of a compound of the invention, or a
 pharmaceutically acceptable salt thereof.

IT 353245-84-8

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses) (platelet ADP receptor inhibitors. and
 therapeutic use)

RN 353245-84-8 CAPLUS

CN Benzeneacetamide, 4-(5-chloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-
 (2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 1 MARPAT COPYRIGHT 2005 ACS on STN
 AN 137:47104 MARPAT Full-text
 TI Preparation of heteroarylsulfonylureas and related compounds as platelet
 ADP receptor antagonists
 IN Scarborough, Robert M.; Jantzen, Hans-michael; Huang, Wolin; Sedlock,
 David M.; Marlowe, Charles K.; Kane-Maguire, Kim A.
 PA USA
 SO U.S. Pat. Appl. Publ., 193 pp., Cont.-in-part of U.S. Ser. No. 755,812.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002077486	A1	20020620	US 2001-920325	20010802
	WO 2001057037	A1	20010809	WO 2001-US3585	20010205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002025961	A1	20020228	US 2001-775812	20010205
EP	1412364	A1	20040428	EP 2002-750339	20020725
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO	2003011872	A1	20030213	WO 2002-US23909	20020726
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003162774	A1	20030828	US 2003-350883	20030123
	US 6689786	B2	20040210		
	US 2004147576	A1	20040729	US 2004-759396	20040115
PRAI	US 2000-180208P	20000204			
	US 2000-202072P	20000505			
	US 2000-230447P	20000906			
	US 2001-775812	20010205			
	WO 2001-US3585	20010205			
	US 2001-920325	20010802			
	WO 2002-US23909	20020726			
	US 2003-350883	20030123			
AB	DWN(E)C(:Y)NHSO2A, DWC(:Y)NHSO2A, DWN(E)C(:Y)NHCH2A, DWN(E)C(SZ):NSO2A, etc.; [A = (substituted) aryl, heteroaryl, alkylaryl, alkylheteroaryl; W = (substituted) aryl, heteroaryl; D = NR1COR2, OR1, specified heteroaryl; E = H, alkyl, polyhaloalkyl, cycloalkyl, alkylaryl, (substituted) aryl, heteroaryl; Z = alkyl; R1 = H, alkyl, polyhaloalkyl,				


cycloalkyl, alkylaryl, alkylcarbonyl, (substituted) arylcarbonyl, aryl, heteroaryl, heteroarylcarbonyl; R2 = (substituted) aryl, heteroaryl; R1R2 = bond, atoms to form a C1-8 chain], were prepared as inhibitors of ADP-mediated platelet aggregation (no data). Thus, N-(4-amino-2-methylphenyl)-4-chlorophthalimide di-Me N-cyanodithioiminocarbonate were stirred in pyridine at 115° for 8 h to give a residue. The residue was heated with DBU, DMAP, and 5-chlorothiophene-2-sulfonamide in pyridine at 115° for 23 h to give 5-chloro-2-[4-[[[(5-chlorothiophen-2-yl)sulfonyl]amino](cyanoimino)methyl]amino]-2-methylphenyl]benzo[c]azolidine-1,3-dione.

MSTR 1




G1 = thienyl (SO (1-2) G15)


G2 = 160-1 163-3



G3 = 61



G6 = 20-2 23-4



G7 = O

G13 = CH

MPL: claim 1

NTE: or pharmaceutically acceptable salts and prodrugs